Intense research is ongoing regarding strategies to target oncogenic FGFR1 and several clinical trials to evaluate the efficacy of various FGFR inhibitors in patients with lung cancer are currently active or have already been completed [10, 14, 15]. The gene discussed is FGFR1; the disease is lung carcinoma.